Ultimately, as HIS mice are becoming part of several translational programs to test or compare immunotherapies against cancer, the next experimental challenge will be to match the HLAs of the HPCs and HLAs expressed in mice and HLAs in the tumor. This evidence concerns the gene HLA-S and neoplasm.